{"id":"W2889696341","doi":"10.1200/jco.2017.35.15_suppl.tps3621","title":"The CCTG CO.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; BC Cancer Agency; University of Ottawa; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Durvalumab; Irinotecan; Tremelimumab; Internal medicine; Oncology; Colorectal cancer; Pembrolizumab; Oxaliplatin; Cancer; Immunotherapy; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00145947,0.002007606,0.002990093,0.0005177013,0.0004894825,0.001219956,0.001072235,0.001906703,0.008700865],"category_scores_gemma":[0.001386375,0.0005702201,0.001482524,0.0005301203,0.0009506829,0.0009639505,0.0004415365,0.003790392,0.001608324],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001813253,"about_ca_system_score_gemma":0.002023425,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003695658,"about_ca_topic_score_gemma":0.01113071,"domain_scores_codex":[0.9993916,0.000309534,0.00001869595,0.00009650234,0.0000495491,0.0001340738],"domain_scores_gemma":[0.9990754,0.0001655537,0.0002114296,0.00004906515,0.00005098769,0.0004475393],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9757283,0.005395347,0.0008181889,0.00055261,0.0006356353,0.0000665861,0.00003256976,0.0003311578,0.002218091,0.0001556051,0.003098937,0.01096688],"study_design_scores_gemma":[0.9633765,0.03359915,0.001440935,0.00002721529,0.0002556916,0.00004898813,0.00001620959,0.00030077,0.0001293879,0.00008711941,0.0007055656,0.00001249534],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9732137,0.006519065,0.0004899486,0.00247415,0.001228118,0.006188468,0.003607237,0.0002266119,0.00605253],"genre_scores_gemma":[0.9679382,0.003754317,0.001599461,0.003307665,0.001107494,0.006927731,0.004541154,0.00007130841,0.01075269],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008700865,"threshold_uncertainty_score":0.02910733,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05437149275475614,"score_gpt":0.443296888580971,"score_spread":0.3889253958262149,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}